Skip to Content
Get your OA knee pain info kit SAUS.HYL.17.06.4040

Diflunisal Pregnancy and Breastfeeding Warnings

Diflunisal is also known as: Dolobid

Diflunisal Pregnancy Warnings

A recent review discussed results from a surveillance study of Michigan Medicaid recipients with completed pregnancies. A total of 258 newborns had been exposed to diflunisal during the first trimester of pregnancy. While only 10 major defects were expected, 19 (7.4%) occurred in this population. One cardiovascular defect (3 expected), one oral cleft (0.4 expected), one case of polydactyly (one expected), and one case of hypospadias (one expected) were noted. Descriptions of the remaining defects were not noted. The contribution of diflunisal to the increased incidence in birth defects in this population remains to be seen.

Diflunisal has been assigned to pregnancy category C by the FDA. Some animal studies have revealed evidence of embryotoxicity and teratogenicity. There are no controlled data in human pregnancy. In one surveillance study, nineteen major birth defects were noted in 258 pregnancies with diflunisal use in the first trimester. In addition, use late in pregnancy may cause premature closure of the ductus arteriosus and prolong labor and delivery. Diflunisal should only be given during pregnancy when benefit outweighs risk. Diflunisal should be avoided near term.

See references

Diflunisal Breastfeeding Warnings

Diflunisal is excreted into human milk in small amounts. Milk concentrations range from 2% to 7% of corresponding maternal serum concentrations. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue diflunisal, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. Briggs GG, Freeman RK, Yaffe SJ "Diflunisal." Drugs in Pregnancy and Lactation Update 6 (1993): 18-9
  2. "Product Information. Dolobid (diflunisal)." Merck & Co, Inc, West Point, PA.

References for breastfeeding information

  1. "Product Information. Dolobid (diflunisal)." Merck & Co, Inc, West Point, PA.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.